Exploratory digital outcome measures of motor sign progression in Parkinson's disease patients treated with prasinezumab.

Saved in:
Bibliographic Details
Title: Exploratory digital outcome measures of motor sign progression in Parkinson's disease patients treated with prasinezumab.
Authors: Taylor KI; Roche Pharma Research and Early Development (pRED) Neuroscience & Rare Diseases, Data & Analytics, Pharmaceutical Sciences, Clinical Pharmacology, Roche Innovation Center Basel, F. Hoffmann-La Roche Ltd., Basel, Switzerland. kirsten.taylor@roche.com., Lipsmeier F; Roche Pharma Research and Early Development (pRED) Neuroscience & Rare Diseases, Data & Analytics, Pharmaceutical Sciences, Clinical Pharmacology, Roche Innovation Center Basel, F. Hoffmann-La Roche Ltd., Basel, Switzerland.; Roche Information Solutions (RIS) Data & Analytics, Roche Diagnostics, F. Hoffmann-La Roche Ltd., Basel, Switzerland., Scelsi MA; Product Development Data Sciences, Roche Products Ltd, Welwyn Garden City, UK.; Chiesi Group, Manchester, United Kingdom., Volkova-Volkmar E; Roche Pharma Research and Early Development (pRED) Neuroscience & Rare Diseases, Data & Analytics, Pharmaceutical Sciences, Clinical Pharmacology, Roche Innovation Center Basel, F. Hoffmann-La Roche Ltd., Basel, Switzerland., Rukina D; Roche Pharma Research and Early Development (pRED) Neuroscience & Rare Diseases, Data & Analytics, Pharmaceutical Sciences, Clinical Pharmacology, Roche Innovation Center Basel, F. Hoffmann-La Roche Ltd., Basel, Switzerland., Popp W; Roche Pharma Research and Early Development (pRED) Neuroscience & Rare Diseases, Data & Analytics, Pharmaceutical Sciences, Clinical Pharmacology, Roche Innovation Center Basel, F. Hoffmann-La Roche Ltd., Basel, Switzerland., Lambrecht S; Roche Pharma Research and Early Development (pRED) Neuroscience & Rare Diseases, Data & Analytics, Pharmaceutical Sciences, Clinical Pharmacology, Roche Innovation Center Basel, F. Hoffmann-La Roche Ltd., Basel, Switzerland., Anzures-Cabrera J; Product Development Data Sciences, Roche Products Ltd, Welwyn Garden City, UK., Summers D; Product Development Data Sciences, Roche Products Ltd, Welwyn Garden City, UK., Abt M; Product Development Data Sciences, Hoffmann-La Roche Ltd., Basel, Switzerland., Monnet A; Product Development Data Sciences, Hoffmann-La Roche Ltd., Basel, Switzerland., Kilchenmann T; Roche Pharma Research and Early Development (pRED) Neuroscience & Rare Diseases, Data & Analytics, Pharmaceutical Sciences, Clinical Pharmacology, Roche Innovation Center Basel, F. Hoffmann-La Roche Ltd., Basel, Switzerland., Schjodt-Eriksen J; Roche Pharma Research and Early Development (pRED) Neuroscience & Rare Diseases, Data & Analytics, Pharmaceutical Sciences, Clinical Pharmacology, Roche Innovation Center Basel, F. Hoffmann-La Roche Ltd., Basel, Switzerland.; Roche Information Solutions (RIS) Data & Analytics, Roche Diagnostics, F. Hoffmann-La Roche Ltd., Basel, Switzerland., Essioux L; Product Development Data Sciences, Hoffmann-La Roche Ltd., Basel, Switzerland.; Computer Science Resource and Research Center, Institut Pasteur, Paris, France., Kustermann T; Roche Pharma Research and Early Development (pRED) Neuroscience & Rare Diseases, Data & Analytics, Pharmaceutical Sciences, Clinical Pharmacology, Roche Innovation Center Basel, F. Hoffmann-La Roche Ltd., Basel, Switzerland., Zago W; Prothena Biosciences Inc, South San Francisco, California, USA., Svoboda H; Roche Pharma Research and Early Development (pRED) Neuroscience & Rare Diseases, Data & Analytics, Pharmaceutical Sciences, Clinical Pharmacology, Roche Innovation Center Basel, F. Hoffmann-La Roche Ltd., Basel, Switzerland.; Roche Innovation Center Basel, and Product Development Neuroscience, F. Hoffmann-La Roche Ltd., Basel, Switzerland., Nikolcheva T; Roche Innovation Center Basel, and Product Development Neuroscience, F. Hoffmann-La Roche Ltd., Basel, Switzerland., Postuma RB; Department of Neurology, McGill University, Montreal General Hospital, Montreal, Quebec, Canada., Pagano G; Roche Pharma Research and Early Development (pRED) Neuroscience & Rare Diseases, Data & Analytics, Pharmaceutical Sciences, Clinical Pharmacology, Roche Innovation Center Basel, F. Hoffmann-La Roche Ltd., Basel, Switzerland.; University of Exeter Medical School, London, United Kingdom., Lindemann M; Roche Pharma Research and Early Development (pRED) Neuroscience & Rare Diseases, Data & Analytics, Pharmaceutical Sciences, Clinical Pharmacology, Roche Innovation Center Basel, F. Hoffmann-La Roche Ltd., Basel, Switzerland.; Roche Information Solutions (RIS) Data & Analytics, Roche Diagnostics, F. Hoffmann-La Roche Ltd., Basel, Switzerland.
Corporate Authors: PASADENA Investigators, Prasinezumab Study Group
Source: NPJ digital medicine [NPJ Digit Med] 2025 Jun 16; Vol. 8 (1), pp. 365. Date of Electronic Publication: 2025 Jun 16.
Publication Type: Journal Article
Journal Info: Publisher: Nature Publishing Group Country of Publication: England NLM ID: 101731738 Publication Model: Electronic Cited Medium: Internet ISSN: 2398-6352 (Electronic) Linking ISSN: 23986352 NLM ISO Abbreviation: NPJ Digit Med Subsets: PubMed not MEDLINE
Database: MEDLINE Ultimate
Description
ISSN:2398-6352
DOI:10.1038/s41746-025-01572-8